Clinical impact of PSMA-based ¹⁸F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy.

ABSTRACT:

Purpose

The purpose of our study was to assess ¹⁸F-DCFBC PET/CT, a PSMA targeted PET agent, for lesion detection and clinical management of biochemical relapse in prostate cancer patients after primary treatment.

Methods

This is a prospective IRB-approved study of 68 patients with documented biochemical recurrence after primary local therapy consisting of radical prostatectomy (n = 50), post radiation therapy (n = 9) or both (n = 9), with negative conventional imaging. All 68 patients underwent whole-body ¹⁸F-DCFBC PET/CT, and 62 also underwent mpMRI within one month. Lesion detection with ¹⁸F-DCFBC was correlated with mpMRI findings and pre-scan PSA levels. The impact of ¹⁸F-DCFBC PET/CT on clinical management and treatment decisi

SUBMITTER: Mena E 

PROVIDER: S-EPMC7983162 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature